The CompassHER2 RD phase III randomized trial is investigating whether adding tucatinib to trastuzumab emtansine (T-DM1) improves relapse-free outcomes compared with T-DM1 alone in patients with HER2-positive breast cancer and residual disease following neoadjuvant therapy. The double-blinded trial is currently active but no longer enrolling.
The CompassHER2 Residual Disease (RD) trial is a double-blinded, phase III randomized study sponsored by the Alliance for Clinical Trials in Oncology, designed to determine whether dual HER2 blockade with T-DM1 plus tucatinib offers superior relapse prevention over T-DM1 monotherapy in high-risk HER2-positive breast cancer. The trial targets a population with residual invasive disease after neoadjuvant HER2-directed therapy—a group known to carry elevated recurrence risk despite standard adjuvant T-DM1.
T-DM1 (trastuzumab emtansine) functions as an antibody-drug conjugate, combining the HER2-targeted monoclonal antibody trastuzumab with the cytotoxic microtubule inhibitor DM1. Tucatinib, a selective HER2-directed tyrosine kinase inhibitor, provides complementary intracellular HER2 pathway suppression. The mechanistic rationale for combining these agents is that concurrent extracellular and intracellular HER2 blockade may more completely abrogate oncogenic signaling and reduce residual micrometastatic burden.
Eligible participants include those with AJCC v8 stage I–III invasive HER2-positive breast carcinoma—including multifocal and synchronous bilateral presentations—who have residual disease at surgery. Secondary endpoints incorporate quality-of-life assessments, reflecting interest in tolerability alongside efficacy outcomes. The trial is currently active but closed to new enrollment (NCT04457596).
Key points
- Phase III, double-blinded RCT comparing T-DM1 plus tucatinib versus T-DM1 plus placebo in HER2-positive breast cancer with residual disease post-neoadjuvant therapy
- Tucatinib adds selective intracellular HER2 tyrosine kinase inhibition to the extracellular/cytotoxic mechanism of T-DM1, providing dual-pathway HER2 blockade
- Eligible population spans AJCC v8 stage I–III invasive HER2-positive carcinoma, including multifocal and bilateral disease presentations
- Trial is active but no longer recruiting (NCT04457596); sponsored by the Alliance for Clinical Trials in Oncology
- Quality-of-life assessments are incorporated as secondary endpoints alongside relapse-free survival outcomes
Why it matters
Residual HER2-positive disease after neoadjuvant therapy confers significant recurrence risk even with adjuvant T-DM1; if the combination strategy demonstrates superiority, it could redefine the adjuvant standard of care for this high-risk subset. Results from CompassHER2 RD may also inform sequencing strategies for HER2-directed agents in the curative setting.